Real-world effectiveness of tofacitinib on ulcerative colitis-associated spondyloarthropathy: A multicenter prospective study from the Italian group for the study of inflammatory bowel diseases (IG-IBD)
Ther Adv Gastroenterol 2025;18:1–11 Doi: 10.1177/17562848251367559
In patients with UC and refractory spondyloarthritis (SpA)—many of whom had previously failed multiple biologic therapies—TOF demonstrated effectiveness, particularly in those with peripheral SpA. Macaluso et al. assessed the effectiveness of TOF in UC-associated SpA. Articular responses were evaluated using rheumatologic scores.
This is the first prospective study specifically designed to assess IBD-associated SpA. Authors observed a differential response based on SpA phenotype. Patients with peripheral SpA had significantly higher rates of steroid-free joint response compared to those with axial or mixed disease.
Keywords:
